Latest Period
Q1 2026
Security Snapshot
Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) Institutional Ownership
CUSIP: 01438T106
13F Institutional Holders and Ownership History from Q2 2014 to Q1 2026
Institutions Reporting
119
Shares (Excl. Options)
36,975,676
Price
$1.69
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- ALDX on Nasdaq
- Shares outstanding
- 59,794,743
- Price per share
- $1.50
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 36,975,676
- Total reported value
- $62,484,613
- % of total 13F portfolios
- 0%
- Share change
- -1,035,531
- Value change
- -$20,172,097
- Number of holders
- 119
- Price from insider filings
- $1.50
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ALDX - Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 01438T106.
- 119 institutions reported positions in Q1 2026.
- Schedule 13D/13G significant owner rows are not currently available.
What Changed
- Holder count moved from 134 to 119 between Q4 2025 and Q1 2026.
- Reported value moved from $201,592,852 to $62,484,613.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 119 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 01438T106?
CUSIP 01438T106 identifies ALDX - Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 01438T106:
As of 31 Mar 2026, 119 institutional investors reported holding 36,975,676 shares of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX). This represents 62% of the company’s total 59,794,743 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 9.2% | 5,475,516 | 0% | 5.1% | $9,253,622 |
| BlackRock, Inc. | 6.3% | 3,763,887 | -2.2% | 0% | $6,360,969 |
| AQR CAPITAL MANAGEMENT LLC | 4.7% | 2,829,875 | +131% | 0% | $4,782,489 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 2,363,742 | 0% | 0% | $3,994,724 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 3.6% | 2,152,315 | +16% | 0.61% | $3,637,412 |
| 683 Capital Management, LLC | 2.5% | 1,500,000 | -2% | 0.24% | $2,534,999 |
| D. E. Shaw & Co., Inc. | 2.3% | 1,403,990 | -12% | 0% | $2,372,743 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 1,251,652 | +6.9% | 0% | $2,115,714 |
| STATE STREET CORP | 1.9% | 1,124,710 | +2.4% | 0% | $1,900,760 |
| MILLENNIUM MANAGEMENT LLC | 1.7% | 995,243 | +2159% | 0% | $1,681,961 |
| JANE STREET GROUP, LLC | 1.6% | 968,891 | +219% | 0% | $1,637,425 |
| ARDSLEY ADVISORY PARTNERS LP | 1.6% | 950,000 | -34% | 0.24% | $1,605,500 |
| RENAISSANCE TECHNOLOGIES LLC | 1.4% | 863,187 | +147% | 0% | $1,458,786 |
| ACADIAN ASSET MANAGEMENT LLC | 1.4% | 858,288 | -12% | 0% | $1,446,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.4% | 807,778 | 0% | 0% | $1,365,145 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1.3% | 796,816 | -18% | 0.01% | $1,346,619 |
| Propel Bio Management, LLC | 1.2% | 730,606 | 0.78% | $1,234,724 | |
| DIMENSIONAL FUND ADVISORS LP | 1% | 624,170 | +1.9% | 0% | $1,054,812 |
| GOLDMAN SACHS GROUP INC | 0.91% | 543,146 | +78% | 0% | $917,917 |
| UBS Group AG | 0.9% | 537,569 | +462% | 0% | $908,492 |
| MORGAN STANLEY | 0.87% | 518,642 | -21% | 0% | $876,505 |
| NORTHERN TRUST CORP | 0.63% | 374,812 | -1.2% | 0% | $633,433 |
| VANGUARD FIDUCIARY TRUST CO | 0.57% | 338,621 | 0% | 0% | $572,269 |
| HRT FINANCIAL LP | 0.48% | 286,444 | 0% | $484,000 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.47% | 278,442 | +343% | 0% | $470,567 |
Institutional Holders of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 36,975,676 | $62,484,613 | -$20,172,097 | $1.69 | 119 |
| 2025 Q4 | 38,929,706 | $201,592,852 | -$2,038,251 | $5.18 | 134 |
| 2025 Q3 | 39,091,752 | $204,002,195 | +$26,942,734 | $5.22 | 129 |
| 2025 Q2 | 34,234,495 | $131,165,420 | -$14,803,182 | $3.83 | 121 |
| 2025 Q1 | 37,522,553 | $215,581,662 | +$3,357,660 | $5.75 | 124 |
| 2024 Q4 | 37,181,780 | $185,566,183 | +$2,534,433 | $4.99 | 117 |
| 2024 Q3 | 36,411,204 | $196,355,871 | +$6,362,230 | $5.39 | 111 |
| 2024 Q2 | 35,332,656 | $116,899,840 | -$329,270 | $3.31 | 103 |
| 2024 Q1 | 35,411,236 | $115,798,928 | +$808,753 | $3.27 | 101 |
| 2023 Q4 | 35,121,957 | $123,276,317 | -$16,780,776 | $3.51 | 103 |
| 2023 Q3 | 37,775,090 | $252,308,601 | -$9,900,512 | $6.68 | 120 |
| 2023 Q2 | 39,037,773 | $327,514,881 | +$24,184,461 | $8.39 | 119 |
| 2023 Q1 | 35,585,837 | $353,348,951 | +$15,344,761 | $9.93 | 107 |
| 2022 Q4 | 34,171,691 | $237,833,495 | -$18,830,170 | $6.96 | 93 |
| 2022 Q3 | 36,966,565 | $197,399,795 | +$1,459,079 | $5.34 | 85 |
| 2022 Q2 | 36,943,694 | $147,408,805 | -$7,357,330 | $3.99 | 88 |
| 2022 Q1 | 38,636,557 | $171,807,935 | +$10,287,580 | $4.44 | 102 |
| 2021 Q4 | 36,272,402 | $145,130,796 | -$44,887,818 | $4.00 | 110 |
| 2021 Q3 | 39,720,964 | $348,695,759 | -$60,891,971 | $8.78 | 114 |
| 2021 Q2 | 45,258,901 | $512,794,552 | +$153,473,538 | $11.33 | 130 |
| 2021 Q1 | 31,692,851 | $376,513,639 | +$122,609,589 | $11.88 | 107 |
| 2020 Q4 | 22,091,649 | $151,541,784 | -$10,169,396 | $6.86 | 95 |
| 2020 Q3 | 23,807,765 | $176,308,405 | +$68,333,848 | $7.41 | 84 |
| 2020 Q2 | 14,645,367 | $61,066,116 | -$6,590,170 | $4.17 | 79 |
| 2020 Q1 | 16,769,610 | $41,415,535 | -$6,410,268 | $2.47 | 69 |
| 2019 Q4 | 17,701,121 | $102,840,148 | +$1,433,085 | $5.81 | 76 |
| 2019 Q3 | 16,864,477 | $88,888,097 | -$685,228 | $5.27 | 70 |
| 2019 Q2 | 16,888,317 | $101,327,468 | +$1,168,639 | $6.00 | 75 |
| 2019 Q1 | 16,361,337 | $147,746,642 | -$6,160,793 | $9.03 | 77 |
| 2018 Q4 | 17,157,946 | $141,481,000 | -$15,993,709 | $8.30 | 75 |
| 2018 Q3 | 18,046,261 | $248,653,190 | +$81,737,278 | $13.80 | 90 |
| 2018 Q2 | 12,131,183 | $96,444,142 | +$14,632,796 | $7.95 | 65 |
| 2018 Q1 | 10,285,308 | $77,138,000 | +$3,821,299 | $7.50 | 42 |
| 2017 Q4 | 9,777,889 | $66,488,000 | +$3,712,599 | $6.80 | 35 |
| 2017 Q3 | 9,221,517 | $66,394,000 | +$13,267,111 | $7.20 | 35 |
| 2017 Q2 | 7,437,286 | $34,736,000 | -$2,554,099 | $4.65 | 24 |
| 2017 Q1 | 7,897,813 | $37,958,000 | +$8,366,763 | $5.00 | 24 |
| 2016 Q4 | 6,136,618 | $32,831,000 | +$111,606 | $5.35 | 20 |
| 2016 Q3 | 6,112,780 | $47,882,100 | -$1,304,703 | $7.82 | 22 |
| 2016 Q2 | 6,358,443 | $36,177,450 | +$11,374,826 | $5.69 | 25 |
| 2016 Q1 | 4,372,667 | $18,317,243 | -$231,292 | $4.19 | 26 |
| 2015 Q4 | 4,427,755 | $30,018,000 | +$376,484 | $6.78 | 20 |
| 2015 Q3 | 4,330,050 | $25,241,000 | +$608,221 | $5.83 | 22 |
| 2015 Q2 | 4,225,512 | $32,853,000 | +$19,634,402 | $7.76 | 23 |
| 2015 Q1 | 1,691,795 | $17,415,000 | +$8,386,368 | $10.18 | 15 |
| 2014 Q4 | 870,129 | $6,277,000 | +$82,000 | $7.18 | 5 |
| 2014 Q3 | 859,337 | $5,163,000 | +$34,237 | $5.74 | 6 |
| 2014 Q2 | 852,047 | $5,639,000 | +$5,638,000 | $6.56 | 5 |